RADNOSTIX INC
INISAbout the company
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
1 / 15
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2167 (Top 70%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-12 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-12 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio7.2x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-3.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-3.8%, ROC=-36.1%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)42.6x✗Dreman< 8xPrice / Book Value per Share7.2x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-3.9%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=0.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=7.2x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share307.1x✗Ackman<= 25Price vs. Trailing Low125% of trailing low ($0.04)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-10.83%; #4214/6340 (top 66.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.0715; #4891/6449 (top 75.8%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+417.2%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.4243; #2847/5247 (top 54.3%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-3.50%; #2863/4519 (top 63.4%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-44.44%; #4967/6202 (top 80.1%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 2✗ 11▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -3.9% vs Rev: -23.7%✗LynchInventory growth < Revenue growthEPS Growth Direction$-0.02 (2010) -> $0.00 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency3/16 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth9.7%✓Ackman>= 5%Positive EPS Growth Frequency0/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 60.2% -> 58.9%, operating margin -6.3% -> -7.3%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR6.9%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✗ 11▾
All 8 investors flag INIS's efficiency
Current Ratio0.84✗Graham>= 2.0ROIC (3-5 yr avg)-28.6%✗Buffett> 10%ROIC - WACC-38.6%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-36.1%✗Greenblatt> 25%Current Ratio Change YoY1.50 -> 1.16✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.81x -> 0.73x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities0.84✗Dreman> 1.5Return on Invested Capital-121.1%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-14.6%; FY2024: ROIC=0.1%; FY2025: ROIC=-19.6%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -19.6%)✗SleepROIC > 12% in a majority of years - Verdicts0% pass✗ 16▾
Split decision: 15 FAIL · 1 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2167✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1705/2370 (Top 71.9%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Profitability6% pass✓ 3✗ 32▾
15 of 16 flag INIS's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)1/19 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)3/19 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-14.4%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-7.3% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-1.0M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-151.4%✗Lynch> 15%EBIT / Enterprise Value-3.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-3.8%, ROC=-36.1%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-5.09%✗PiotroskiROA > 0ROA Change YoY0.05% -> -5.09% (delta: -5.14%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=3.48%, ROA=-5.09%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY62.2% -> 58.9%✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-151.4%✗Dreman> 12%Margin of SafetyP/B=7.2x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-15.3% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency3/16 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-25.8%✗Ackman>= 15%Net Income / Shareholders Equity-151.4%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-6.3% (2023) -> -7.3% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 60.2% -> 58.9%, operating margin -6.3% -> -7.3%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-10.83%; #4214/6340 (top 66.5%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+36.28%; #1117/3702 (top 30.2%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-151.39%; #4782/5226 (top 91.5%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0310; #1953/5884 (top 33.2%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years1/9 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Cash Flow10% pass✓ 2✗ 10▾
9 of 10 flag INIS's cash flow — Buffett, Lynch, Dreman +6 more
Free Cash Flow Proxy$-1.0M✗BuffettPositive and growingFCF Positive and Growing$-0.9M✗LynchPositive and growingOperating Cash Flow$0.6M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=3.48%, ROA=-5.09%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)42.6x✗Dreman< 8xP/E or FCF YieldFCF Yield=0.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive6/14 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-3.5%✗Ackman>= 4%Price / FCF per Share307.1x✗Ackman<= 25Positive Operating Cash Flow frequency8/18 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-0.9M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-3.50%; #2863/4519 (top 63.4%)✗OshaughnessyTop 10% of eligible cross-section - Debt & Leverage50% pass✓ 9✗ 6▾
6 of 12 pass — Graham, Buffett, Lynch +3 more object
LT Debt vs Net Current AssetsLT Debt $1.9M vs NCA $0.7M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.00, IC: -8.5x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0✓Lynch< 0.33Cash - Long-term Debt$-0.2M✗LynchPositive preferredLT Debt / Total Assets Change12.86% -> 10.83%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.84✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-8.5x, D/EBITDA=0.0x (no debt)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)✓AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 0.9% of shares last year, 1.6% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, interest expense, depreciation amortization. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | $26.5Mcurrent | -- | -- | $37.0Mest. | $20.9Mest. | $26.0Mest. | $20.6Mest. | $45.3Mest. |
| Revenue | $11.2M↓24% | $2.7M↓27% | $2.4M↓27% | $13.1M↓6% | $13.9M↑13% | $12.3M↑10% | $11.2M↑16% | $9.7M |
| Operating Income | -$2.9M↓1245% | -$834.2K↓519% | -$1.3M↓1915% | -$956.2K↓13956% | $6.9K↑101% | -$776.3K↑35% | -$1.2M↓77% | -$680.8K |
| Net Income | -$2.9M↓2437% | -$882.0K↓449% | -$1.3M↓1096% | -$908.0K↓10690% | $8.6K↑101% | -$869.0K↓387% | $303.2K↑134% | -$902.3K |
| EPS (Diluted) | -- | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Margin | 53.8%↓11% | 50.9%↓13% | 48.4%↓23% | 58.9%↓5% | 62.2%↑3% | 60.2%↑7% | 56.3%↓5% | 59.4% |
| Operating Margin | -25.8%↓1601% | -31.2%↓746% | -55.1%↓2643% | -7.3%↓14835% | 0.0%↑101% | -6.3%↑41% | -10.8%↓53% | -7.0% |
| ROE | -151.4%↓5368% | — | — | -24.6%↓12566% | 0.2%↑101% | -21.5%↓408% | 7.0%↑121% | -33.0% |
| Total Debt | $0 | $0 | $0 | $162.7K↓47% | $308.4K↑98% | $155.7K↑170% | $57.8K↓83% | $347.8K |
| Shareholders' Equity | $1.9M↓56% | $1.9M↓56% | $2.6M↓39% | $3.7M↓15% | $4.3M↑8% | $4.0M↓7% | $4.3M↑59% | $2.7M |
| Current Ratio | 0.84↓43% | 0.84↓43% | 0.88↓11% | 1.16↓22% | 1.50↓15% | 1.76↑8% | 1.63↑147% | 0.66 |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.04↓38% | 0.07↑84% | 0.04↑190% | 0.01↓90% | 0.13 |
| Operating Cash Flow | -$376.3K↓157% | -$613.6K↓294% | -$72.4K↓1315% | $620.2K↓3% | $638.8K↑10% | $582.6K↑139% | -$1.5M↓825% | -$161.9K |
| Free Cash Flow | -$925.2K↓2469% | -$613.6K↓341% | -$277.6K↓107% | $86.0K↑204% | -$82.4K↓119% | $433.5K↑127% | -$1.6M↓340% | -$367.4K |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Measuring and Control Equipment
INIS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC.TMO | $259.4B | $700.22 | $44.6B | $6.7B | 12.6% | 0.74 | 17.4% | 1.89 | 3/9 | 3/9 | 3/7 | 1/3 | F-Score 5 | 7/11 |
| DANAHER CORP /DE/DHR | $163.9B | $233.02 | $24.6B | $3.6B | 6.9% | 0.35 | 19.1% | 1.87 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 4/11 |
| WATERS CORP /DE/WAT | $90.5B | $460.25 | $3.2B | $642.6M | 25.1% | 0.55 | 25.4% | 1.73 | 1/9 | 4/9 | 1/7 | 0/3 | F-Score 4 | 5/11 |
| AGILENT TECHNOLOGIES, INC.A | $49.0B | $173.96 | $6.9B | $1.3B | 19.3% | 0.45 | 21.3% | 1.96 | 2/9 | 5/9 | 3/7 | 1/3 | F-Score 5 | 5/11 |
| ROPER TECHNOLOGIES INCROP | $47.5B | $479.98 | $7.9B | $1.5B | 7.7% | 0.47 | 28.3% | 0.52 | 2/9 | 3/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| COHERENT CORP.COHR | $43.0B | $218.15 | $5.8B | $49.4M | 0.9% | 0.69 | 1.6% | 2.19 | 3/9 | 1/9 | 0/7 | 0/3 | F-Score 4 | 4/11 |
| TERADYNE, INCTER | $39.0B | $249.55 | $3.2B | $554.0M | 19.8% | 0.07 | 20.4% | 1.75 | 2/9 | 6/9 | 4/7 | 1/3 | F-Score 6 | 6/11 |
| ILLUMINA, INC.ILMN | $31.3B | $207.01 | $4.3B | $850.0M | 31.2% | 0.73 | 18.6% | 2.08 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |